Frederick E. Munschauer
1 Papers
Frederick E. Munschauer is an academic researcher. The author has contributed to research in topics: Internal medicine & Randomized controlled trial. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruce A.C. Cree,Gary Cutter,Jerry S. Wolinsky,M. S. Freedman,Giancarlo Comi,Gavin Giovannoni,Hans-Peter Hartung,Douglas L. Arnold,Jens Kuhle,Valerie J Block,Frederick E. Munschauer,Frédéric Sedel,Fred D. Lublin,Stephen C. Reingold,Pierre Duquette,Tobias Derfuss,Franz Fazekas,Maria Pia Sormani,Robert P. Lisak,Jennifer Graves,Stephen Krieger,Rana K. Zabad,Scott D. Newsome,Joshua Barton,Richard MacDonell,Mark Marriott,Nina De Klippel,Guy Laureys,Barbara Willekens,Virginia Devonshire,Mark S. Freedman,J. Marc Girard,Paul S. Giacomini,Roger McKelvey,Daniel Selchen,Galina Vorobeychik,Ludivine Witkowski,Radek Ampapa,Jana Lizrova Preiningerova,Eva Meluzinova,R. Talab,Marta Vachova,Orhan Aktas,Mathias Buttmann,Elias Hamp Birte,Tania Kuempfel,Paul Friedemann,Daniela Rau,Gerd Reifschneider,Piotr Sokolowski,Hayrettin Tumani,Maria Satori,Carlo Pozzilli,Agata Klosek,Jozef Koscielniak,Fryze Waldemar,Malgorzata Zajda,Rafael Arroyo Gonzalez,Guillermo Izquierdo Ayuso,Victoria Fernandez Sanchez,Celia Oreja Guevara,Jose Enrique Martinez Rodriguez,Xavier Montalban,Lluís Ramió-Torrentà,Lou Brundin,Jan Lycke,Murat Terzi,Joe Guadagno,Don J. Mahad,Adrian Pace,Klaus Schmierer,Ahmed T. Toosy,Stewart Webb,Mark A. Agius,Lilyana Amezcua,Michelle L Apperson,Bridget Bagert,Daniel Bandari,Evanthia Bernitsas,Jonathan Calkwood,Jonathan Carter,Bruce A. Cohen,Devon S. Conway,Joanna Cooper,John R. Corboy,Patricia K. Coyle,Bruce C.A. Cree,Mitchel Freedman,Corey C. Ford,Edward Fox,Myla D. Goldman,Benjamin Greenberg,Mariko Kita,Thomas Leist,Sharon G. Lynch,Aaron E. Miller,Harold L. Moses,Robert T. Naismith,Mary Ann Picone,Bhatia Perminder,Alexander Rae-Grant,Kottil Rammohan,Anthony T. Reder,Claire S Riley,Derrick Robertson,Vernon Rowe,Shiv Saidha,Lawrence Samkoff,Christopher Severson,Kyle Smoot,Sharon Stoll,Randall Trudell,Bianca Weinstock-Guttman,Sanjay Yathiraj +113 more
TL;DR: This study showed that MD 1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1002 cannot be recommended for treatment of progressive multipleclerosis.